Finance

Beta
Lists
BLRX:TLV
BioLine RX Ltd
ILA 1.50
-6.25%
(-0.10) 1D
Jun 4, 5:26:00 PM GMT+3  ·   ILA
All symbols
SymbolPriceChange% Change
Generating top insights for BLRX...
Open
ILA 1.60
High
ILA 1.60
Low
ILA 1.50
Mkt. cap
15.08M
Avg. vol.
8.19M
Volume
7.31M
52-wk high
ILA 3.90
52-wk low
ILA 1.10
EPS
-ILA 0.00
Shares outstanding
2.62B
No. of employees
22
Open
ILA 1.60
High
ILA 1.60
Low
ILA 1.50
Mkt. cap
15.08M
Avg. vol.
8.19M
Volume
7.31M
52-wk high
ILA 3.90
52-wk low
ILA 1.10
EPS
-ILA 0.00
Shares outstanding
2.62B
No. of employees
22
News stories
From sources across the web
Profile
BioLineRx Ltd., or BioLine, is a publicly traded drug development company. Headquartered in Israel, its shares are traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange. Wikipedia
About BioLine RX Ltd
CEOPhilip A. Serlin
Employees22
Founded2003
Headquarters-
SectorBiotechnology
Websitebiolinerx.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
304.00K
427.00K
194.00K
477.00K
Cost of goods sold
72.00K
84.00K
40.00K
95.00K
Cost of revenue
72.00K
84.00K
40.00K
95.00K
Research and development expenses
2.33M
1.72M
2.42M
2.53M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
209.00K
831.00K
1.12M
858.00K
Operating expense
2.54M
2.55M
3.54M
3.39M
Total operating expenses
2.61M
2.63M
3.58M
3.48M
Operating income
-2.30M
-2.21M
-3.39M
-3.00M
Other non operating income
-1.85M
1.16M
1.10M
458.00K
EBT including unusual items
-3.94M
-977.00K
-2.24M
-2.59M
EBT excluding unusual items
-3.94M
-977.00K
-2.24M
-2.59M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-3.94M
-977.00K
-1.38M
-1.60M
Net profit margin
-1,296.05%
-228.81%
-713.92%
-335.64%
Earnings per share
-
-
-
-
Interest and investment income
490.00K
377.00K
-
208.00K
Interest expense
-276.00K
-304.00K
-288.00K
-250.00K
Net interest expenses
214.00K
73.00K
-288.00K
-42.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-2.13M
-2.09M
-3.33M
-2.92M
Gain or loss from assets sale
-
-
25.00K
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer